Please use this identifier to cite or link to this item:
|Title:||A rationale for targeting the P2X7 receptor in Coronavirus disease 19||Authors:||Di Virgilio, Francesco
Sarti, Alba Clara
|Keywords Plus:||CONCISE GUIDE;DAMPS||Mesh headings:||Coronavirus Infections;Pneumonia, Viral;Receptors, Purinergic P2X7;Respiratory Distress Syndrome||Secondary Mesh headings:||Animals;Betacoronavirus;COVID-19;Cytokine Release Syndrome;Humans;Macrophages;Pandemics;SARS-CoV-2;T-Lymphocytes||Issue Date:||2020||Publisher:||WILEY||Journal:||British journal of pharmacology||Abstract:||
Severe pneumonia which shares several of the features of acute respiratory distress syndrome (ARDS) is the main cause of morbidity and mortality in Coronavirus disease 19 (Covid-19) for which there is no effective treatment, so far. ARDS is caused and sustained by an uncontrolled inflammatory activation characterized by a massive release of cytokines (cytokine storm), diffuse lung oedema, inflammatory cell infiltration, and disseminated coagulation. Macrophage and T lymphocyte dysfunction plays a central role in this syndrome. In several experimental in vitro and in vivo models, many of these pathophysiological changes are triggered by stimulation of the P2X7 receptor. We hypothesize that this receptor might be an ideal candidate to target in Covid-19-associated severe pneumonia. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.
|Appears in Collections:||Articles|
Show full item record
checked on May 2, 2021
WEB OF SCIENCETM
checked on Nov 28, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.